<SEC-DOCUMENT>0001140361-23-000340.txt : 20230104
<SEC-HEADER>0001140361-23-000340.hdr.sgml : 20230104
<ACCEPTANCE-DATETIME>20230104083531
ACCESSION NUMBER:		0001140361-23-000340
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20221229
ITEM INFORMATION:		Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230104
DATE AS OF CHANGE:		20230104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Eterna Therapeutics Inc.
		CENTRAL INDEX KEY:			0000748592
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				311103425
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11460
		FILM NUMBER:		23504457

	BUSINESS ADDRESS:	
		STREET 1:		1035 CAMBRIDGE STREET
		STREET 2:		SUITE 18A
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02141
		BUSINESS PHONE:		(212) 582-1199

	MAIL ADDRESS:	
		STREET 1:		10531 4S COMMONS DRIVE
		STREET 2:		SUITE 166-550
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Brooklyn ImmunoTherapeutics, Inc.
		DATE OF NAME CHANGE:	20210325

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTN BUZZTIME INC
		DATE OF NAME CHANGE:	20051230

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTN COMMUNICATIONS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>brhc10046238_8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:cef="http://xbrl.sec.gov/cef/2022" xmlns:erna="http://eternatx.com/20221229" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Summit
         Document created using Broadridge PROfile 22.12.1.5105
         Copyright 1995 - 2023 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_2f354ac69bcc48c993312065f84aa0fc" contextRef="c20221229to20221229" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_89b099ef14e5497f9d6decf465b93fa2" contextRef="c20221229to20221229">0000748592</ix:nonNumeric><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_b552152fa97b4f6c96e787e7c685aac8" contextRef="c20221229to20221229">NASDAQ</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="erna-20221229.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20221229to20221229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-29</xbrli:startDate><xbrli:endDate>2022-12-29</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

  <div>
    <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" />
    <div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">UNITED STATES</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>

      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> <br />
        </span></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_93296fbc28f74ea6a7680ba310595bde" contextRef="c20221229to20221229">8-K</ix:nonNumeric></div>

      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> <br />
        </span></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CURRENT REPORT</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</div>

      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> <br />
        </span></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Date of Report (Date of earliest event reported): <span style="font-weight: bold;"><ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_c8e73d47c549437dad8f09f985707a36" contextRef="c20221229to20221229" format="ixt:date-monthname-day-year-en">December 29, 2022</ix:nonNumeric></span></div>

      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> <br />
        </span></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 20pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_aba8908c97c8492190ed2c9006033c56" contextRef="c20221229to20221229">Eterna Therapeutics Inc.</ix:nonNumeric><br />
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">(Exact Name of Registrant as Specified in its Charter)</div>

      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> <br />
        </span></div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 32.61%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_fe49c90992fa4568bdab8fa5de9393bd" contextRef="c20221229to20221229" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 33.68%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_1d4eb8b2a66e4171a2900f93ca312e8a" contextRef="c20221229to20221229">001-11460</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 33%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_99ea217ba72c4119b2ada9cb6fed5bbd" contextRef="c20221229to20221229">31-1103425</ix:nonNumeric><br />
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 32.61%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-style: italic;">(State or Other Jurisdiction of Incorporation)</div>
            </td>

    <td style="width: 33.68%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-style: italic;">(Commission File Number)</div>
            </td>

    <td style="width: 33%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-style: italic;">(IRS Employer Identification No.)</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49.01%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_32ca7ee9fe764a599b9d70ef8761804b" contextRef="c20221229to20221229">1035 Cambridge Street</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" id="Fact_9223e44ac85a405787cfba4396c13499" contextRef="c20221229to20221229">Suite 18A</ix:nonNumeric></div>
            </td>

    <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;"><br />
            </td>

    <td style="width: 49%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;"><br />
            </td>

  </tr>

  <tr>

    <td style="width: 49.01%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_490bed6ccbba416cb00fbf1f39bbc072" contextRef="c20221229to20221229">Cambridge</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_490274e502304678bcac01205363dee7" contextRef="c20221229to20221229">MA</ix:nonNumeric></div>
            </td>

    <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;"><br />
            </td>

    <td style="width: 49%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_7450cc16f2c3403c80be86da31c38d15" contextRef="c20221229to20221229">02141</ix:nonNumeric><br />
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 49.01%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-style: italic;">(Address of Principal Executive Offices)</div>
            </td>

    <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;"><br />
            </td>

    <td style="width: 49%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-style: italic;">(Zip Code)</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Registrant&#8217;s telephone number, including area code: <span style="font-weight: bold;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_7d7eb64598e2456999c7d1ccc182f4a6" contextRef="c20221229to20221229">212</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_29b751987e114c24bd15a6b0ea602deb" contextRef="c20221229to20221229">582-1199</ix:nonNumeric></span></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">10355 Science Center Drive, Suite 150, San Diego, CA 92121</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Former name or address, if changed since last report)</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
        provisions:</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_ba47809d5fd5475ca1d58836870c8e7f" contextRef="c20221229to20221229" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_734f50472dd844119f6ca9bee37e5c86" contextRef="c20221229to20221229" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_12753308bcdb4f37a4524acbcadd3f65" contextRef="c20221229to20221229" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_e62d4b89adb54106bc803cad4748e815" contextRef="c20221229to20221229" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 41.3%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;">Title of each class</div>
            </td>

    <td style="width: 0.96%; vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt;"><br />
            </td>

    <td style="width: 18.76%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;">Trading symbol</div>
            </td>

    <td style="width: 1%; vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt;"><br />
            </td>

    <td style="width: 38%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;">Name of each exchange on which registered</div>
            </td>

  </tr>

  <tr>

    <td style="width: 41.3%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: left;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_59a3fbc5a7f744eb94d03f8386643469" contextRef="c20221229to20221229">Common Stock, par value $0.005 per share</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 0.96%; vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt;"><br />
            </td>

    <td style="width: 18.76%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_9fe88d82eaa144c5b6bf3ef976394d04" contextRef="c20221229to20221229">ERNA</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 1%; vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt;"><br />
            </td>

    <td style="width: 38%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center;"><span style="-sec-ix-hidden:Fact_b552152fa97b4f6c96e787e7c685aac8">The Nasdaq Stock Market LLC</span><br />
              </div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities
        Exchange Act of 1934:</div>

      <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_ff3226c8b6414e38832cc61134961aa6" contextRef="c20221229to20221229" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
        financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /></div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 45pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 3.01</td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">As previously reported in its Current Report on Form 8-K filed with the Securities and Exchange Commission (the &#8220;<span style="text-decoration: underline;">SEC</span>&#8221;) on November 23, 2022, Eterna Therapeutics Inc.
          (the &#8220;<span style="text-decoration: underline;">Company</span>&#8221;) received written notice (the &#8220;<span style="text-decoration: underline;">Notice</span>&#8221;) from The Nasdaq Stock Market LLC (&#8220;<span style="text-decoration: underline;">Nasdaq</span>&#8221;) on November 22, 2022 stating that the Company&#8217;s stockholders&#8217; equity of approximately $8.8 million, as reported in the
          Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, fails to comply with the minimum $10.0 million stockholders&#8217; equity requirement for continued listing on the Nasdaq Global Market in accordance with Nasdaq Listing
          Rule 5450(b)(1)(A).&#160; The Notice provided that the Company may consider applying to transfer the listing of the Company&#8217;s common stock, par value $0.005 per share (the &#8220;<span style="text-decoration: underline;">common stock</span>&#8221;) to The Nasdaq Capital Market, subject to the Company
          submitting an online transfer application, paying the requisite fee and satisfying such market&#8217;s continued listing requirements.</div>

      </div>

      <div>
        <div style="text-align: justify;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
          </span></div>

      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">On December 29, 2022, the Company&#8217;s board of directors (the &#8220;<span style="text-decoration: underline;">Board</span>&#8221;) authorized the Company to apply to transfer the listing of its common stock from the Nasdaq Global
          Market to The Nasdaq Capital Market, and, on&#160; January 2, 2023, the Company applied to transfer the listing of its common stock to The Nasdaq Capital Market (the &#8220;<span style="text-decoration: underline;">Transfer</span>&#8221;).. The Nasdaq Capital Market operates in substantially the same
          manner as The Nasdaq Global Market, with issuers listed on The Nasdaq Capital Market tier required to meet certain financial and corporate governance requirements to qualify for continued listing.&#160; The Company currently expects that, upon
          consummation of the Transfer, the common stock will continue to trade under the symbol &#8220;ERNA&#8221;, and the Company expects to file a Current Report on Form 8-K at such time as it can confirm the date of the Transfer.</div>

      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div><br />
        </div>

      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 45pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 5.02</td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div>
        <div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Appointment of President and Chief Executive Officer</div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>

      </div>

      <div>
        <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">On December 30, 2022, the Board appointed Dr. Matthew Angel as the
            Company&#8217;s President and Chief Executive Officer (principal executive officer) effective January 1, 2023 (the &#8220;<span style="text-decoration: underline;">Start Date</span>&#8221;). Prior to such </span><span style="font-size: 10pt; font-family: 'Times New Roman';">appointment</span><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">, Dr. Angel had been serving as the Company&#8217;s as interim President and Chief Executive Officer.</span></div>

      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div><br />
        </div>

      </div>

      <div>
        <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Dr. Angel, 41 years old, is the co-founder of Factor Bioscience Inc. (&#8220;<span style="text-decoration: underline;">Factor</span>&#8221;), a biotechnology company focused on
          developing mRNA and cell-engineering technologies, and has served as its President, Chief Executive Officer and Chairman of its Board of Directors since 2011. In 2020, Dr. Angel co-founded, Exacis Biotherapeutics Inc., an immuno-oncology company,
          for which he serves as the Scientific Advisory Board Chair. Dr. Angel previously served as the Chief Science Officer, Secretary, Treasurer and as a director of Exacis Biotherapeutics Inc. (&#8220;<span style="text-decoration: underline;">Exacis</span>&#8221;), and as the Chief Science Officer,
          Secretary and as a director of Novellus, Inc. (&#8220;<span style="text-decoration: underline;">Novellus</span>&#8221;), a pre-clinical stage biotechnology company focused on developing engineered cellular medicines using its licensed, patented non-immunogenic mRNA, from 2014 until the sale of
          Novellus to the Company in July 2021 (the &#8220;<span style="text-decoration: underline;">Novellus Acquisition</span>&#8221;). Dr. Angel received a Ph.D from the Massachusetts Institute of Technology in 2012 and a B.S. in Engineering from Princeton University in 2003.</div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">In connection with his appointment as President and Chief Executive
            Officer, the Company entered into an offer letter with Dr. Angel, dated as of December 30, 2022 (the &#8220;<span style="text-decoration: underline;">Angel Offer Letter</span>&#8221;). The Angel Offer Letter offers Dr. Angel at-will employment as the President and Chief Executive Officer for a
            term commencing on the Start Date and continuing until terminated by either the Company or Dr. Angel. Pursuant to the Angel Offer Letter, the Company and Dr. Angel agreed </span><span style="font-family: 'Times New Roman'; font-size: 10pt;">to
            negotiate in good faith and execute and deliver a formal, written employment agreement within 30 days following the date of the Angel Offer Letter, consistent with the terms of the Angel Offer Letter and containing such other terms and
            conditions as are mutually acceptable to Dr. Angel and the Company, including severance provisions and restrictive covenant provisions that appropriately take into account Dr. Angel&#8217;s affiliations with Factor and its affiliated entities (the &#8220;<span style="text-decoration: underline;">Angel

              Employment Agreement</span>&#8221;).</span></div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>

      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      </div>

      <div>
        <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">Under the terms of the Angel Offer Letter, the Company will pay Dr.
            Angel an annual base salary of $350,000, which amount is subject to periodic review by the Board or its compensation committee, and a cash signing bonus equal to $210,959 within ten days of the Start Date, which signing bonus represents the
            salary Dr. Angel would have earned for the period during which he served as interim President and Chief Executive Officer, had the Angel Employment Agreement been in effect at the beginning thereof.&#160; Dr. Angel did not receive a salary or other
            cash compensation during his tenure as interim President and Chief Executive Officer.&#160; Dr. Angel will be eligible to </span><span style="font-family: 'Times New Roman'; font-size: 10pt;">receive a performance bonus equal to two percent of the
            gross proceeds actually received by the Company pursuant to all licensing, option, collaboration, partnership, joint venture, settlement, other similar agreements entered into by the Company, or other actions, judgments, or orders that generate
            cash proceeds to the Company, that are originated, negotiated and/or entered into by the Company during Dr. Angel&#8217;s employment (commencing on May 26, 2022) with the Company, subject to certain conditions to be set forth in the Angel Employment
            Agreement, including that Dr. Angel has not voluntarily resigned other than for good reason or has been terminated for cause.</span></div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">In accordance with the terms of the Angel Offer Letter, Dr. Angel
            is entitled to receive equity awards, consisting of a new time-based nonqualified stock option under the Company&#8217;s </span><span style="font-family: 'Times New Roman'; font-size: 10pt;">Restated 2020 Stock Incentive Plan<span style="color: rgb(0, 0, 0);"> (the &#8220;<span style="text-decoration: underline;">Option Grant</span>&#8221;) within ten days of the Start Date, covering a number of shares of common stock, inclusive of all equity awards previously issued to Dr. Angel, equal to 5.0% of the issued and outstanding shares of
              the common stock as of the Start Date. The exercise price of the Option Grant will equal the fair market value of the shares of common stock underlying the Option Grant. The Option Grant shall vest such that 50% of the aggregate of the Option
              Grant and the option previously granted to Dr. Angel on August 1, 2022 were fully vested on the Start Date and the remaining portion of the Option&#160; </span>Grant will vest in substantially equal monthly installments over the 36 months
            following the Start Date<span style="color: rgb(0, 0, 0);">. Vesting generally requires Dr. Angel&#8217;s continued employment through the relevant vesting date.</span></span></div>

      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div><br />
        </div>

      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">The Angel Offer Letter provides Dr. Angel will be eligible for (a) reimbursement of reasonable business expenses, (b) participation in the Company&#8217;s benefit plans and (c)
          paid vacation days in accordance with the Company&#8217;s policies, as in effect from time to time.</div>

      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div><br />
        </div>

      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">The foregoing description of the Angel Offer Letter is only a summary and is qualified in its entirety by reference to the full text of the Angel Offer Letter, which is filed
          as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference in this Item 5.02.</div>

      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div><br />
        </div>

      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">There are no family relationships between Dr. Angel and any director or executive officer of the Company, and, except as set forth below, Dr. Angel does not have any other
          direct or indirect material interest in any transaction or proposed transaction required to be reported under Item 404(a) of Regulation S-K. There are no arrangements or understandings between Dr. Angel and any other persons pursuant to which he
          was selected as Chief Executive Officer and President.</div>

      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div><br />
        </div>

      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      </div>

      <div>
        <div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Certain Relationships and Related Party Transactions with Dr. Angel</div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>

      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">As previously reported, the Company paid consideration totaling approximately $124.0 million in respect of the Novellus Acquisition, which consisted of (a) $22.8 million in
          cash and (b) approximately 7,022,000 shares of common stock, which under the terms of the agreement and plan of acquisition, dated as of July 16, 2021, by and between the Company, Novellus and the other parties thereto (the &#8220;<span style="text-decoration: underline;">Novellus
            Acquisition Agreement</span>&#8221;), were valued at a total of $102.0 million, based on a price of $14.5253 per share of common stock. In connection with the Novellus Acquisition, (i) Factor, of which Dr. Angel beneficially owns approximately 64% of
          its outstanding equity, received approximately $1.7 million in cash consideration from the Company and approximately 2,581,000 shares of common stock, and (ii) Dr. Angel received approximately $2.0 million in cash consideration from the Company
          and approximately 623,000 shares of common stock. In addition, Dr. Angel also received approximately 286,000 shares of common stock, which the Company had placed in escrow for a period that ended on July 16, 2022 to secure indemnification
          obligations to the Company under the Novellus Acquisition Agreement.</div>

      </div>

      <div>
        <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
          </span></div>

      </div>

      <div>
        <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">
          <div>
            <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">As previously reported, on April 26, 2021, Eterna Therapeutics LLC, formerly known as Brooklyn ImmunoTherapeutics LLC (&#8220;<span style="font-size: 10pt; font-family: 'Times New Roman';"><span style="text-decoration: underline;">Eterna LLC</span></span>&#8221;), a subsidiary of the Company, entered into an exclusive license agreement (the &#8220;<span style="font-size: 10pt; font-family: 'Times New Roman';"><span style="text-decoration: underline;">License
                  Agreement</span></span>&#8221;), with <span style="font-size: 10pt; font-family: 'Times New Roman';">Novellus Therapeutics Limited</span>, a subsidiary of Novellus and, following the Novellus Acquisition, <span style="font-size: 10pt; font-family: 'Times New Roman';">a wholly owned subsidiary of the Company (&#8220;<span style="text-decoration: underline;">Novellus Limited</span>&#8221;)</span>, and <span style="font-size: 10pt; font-family: 'Times New Roman';">Factor Bioscience Limited, a wholly owned subsidiary of Factor
                (&#8220;<span style="text-decoration: underline;">Factor Limited</span>&#8221; and together with Novellus Limited, </span>the &#8220;<span style="font-size: 10pt; font-family: 'Times New Roman';"><span style="text-decoration: underline;">Licensors</span></span>&#8221;), to license the Licensors&#8217; intellectual property and mRNA cell reprogramming
              and gene editing technology for use in the development of certain cell-based therapies to be evaluated and developed for treating human diseases, including certain types of cancer, sickle cell disease, and beta thalassemia. Pursuant to the
              License Agreement, Eterna LLC paid the Licensors a total of $4.0 million in connection with the execution of the License Agreement. The completion of the Novellus Acquisition relieved the Company of potential obligations to pay Novellus
              Limited certain upfront fees, clinical development milestone fees and post-registration royalties under the License Agreement, but the agreements with Factor under the License Agreement and Novellus-Factor License Agreement (as defined below)
              remained unchanged prior to the Amendment (as defined below). <a id="z_Hlk123630028"></a>Pursuant to the License Agreement, Eterna LLC paid Factor Limited an additional $2.5 million in October 2021 and was obligated to pay Factor Limited
              $3.5 million in October 2022, which obligation Factor Limited waived in full in connection with the execution of the MSA (as defined below).</div>

          </div>

        </div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';">As previously reported, on November 22, 2022 (the &#8220;<span style="text-decoration: underline;">Amendment
              Effective Date</span>&#8221;), the Company entered into a First Amendment (the &#8220;<span style="text-decoration: underline;">Amendment</span>&#8221;) to the License Agreement (as amended by the Amendment, the &#8220;<span style="text-decoration: underline;">Amended Factor License Agreement</span>&#8221;), by and among Eterna LLC, Novellus Limited, and
            Factor Limited. Pursuant to the Amendment, among other things, Factor Limited granted to Eterna LLC an exclusive, sublicensable license under certain patents owned by Factor Limited (the &#8220;<span style="text-decoration: underline;">Factor Patents</span>&#8221;) for the purpose of identifying
            and pursuing certain opportunities to grant to third parties sublicenses to the Factor Patents. The Amendment also (i) terminated the Novellus-Factor License Agreement (as defined below), (ii) confirmed Factor&#8217;s grant to Eterna LLC of the
            rights and licenses Novellus Limited previously granted to Eterna LLC under the Novellus-Factor License Agreement on the same terms and conditions as granted by Novellus Limited to Eterna LLC under such agreement, (iii) confirmed that
            sublicense granted by Novellus Limited in accordance with the Novellus-Factor License Agreement to NoveCite, Inc. (the &#8220;<span style="text-decoration: underline;">NoveCite Agreement</span>&#8221;), in which the Company has a 25% ownership interest (&#8220;<span style="text-decoration: underline;">NoveCite</span>&#8221;), survives termination of
            the Novellus-Factor License Agreement; and (iv) removed Novellus from the Amended Factor License Agreement and the NoveCite Agreement and replaced Novellus with Factor Limited as the direct licensor to Eterna LLC and NoveCite under such
            agreements, respectively.</span></div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>

      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt;">On November 1, 2020, Novellus Limited and Factor Limited entered into the Third Amended and Restated Exclusive License Agreement, dated as of November 1, 2020 (the &#8220;<span style="text-decoration: underline;">Novellus-Factor


            License Agreement</span>&#8221;), by and between Novellus Limited and Factor Limited, pursuant to which Factor Limited granted to Novellus Limited an exclusive license under certain patents owned by Factor Limited for the development of certain stem
          cell-based cellular therapies for treating diseases and conditions in humans and animals (the &#8220;<span style="text-decoration: underline;">Novellus-Factor Licensed Technology</span>&#8221;), and under which Novellus Limited in turn, under the License Agreement, granted a sublicense to Eterna LLC
          to use the Novellus-Factor Licensed Technology to develop, use and commercialize certain stem cell-based therapy products for use in the treatment of cancer in humans. As previously reported, on November 1, 2022, one of the delineated milestone
          deadlines for certain regulatory filings required under the Novellus-Factor License Agreement expired, which permitted Factor Limited to terminate the license granted to Novellus Limited thereunder, subject to Factor Limited&#8217;s agreement under the
          License Agreement that upon such a termination of the Novellus-Factor License Agreement, the rights and licenses granted to Eterna LLC by Novellus under the License Agreement would survive such termination of the Novellus-Factor License
          Agreement, and Factor Limited&#8217;s agreement to grant to Eterna LLC such rights and licenses on the same terms and conditions as granted by Novellus Limited to Eterna LLC under the License Agreement, which agreement was effected by the Amendment.&#160;
          Similarly, under the Amendment, the NoveCite Agreement was continued as a direct license between Factor Limited and NoveCite.</div>

      </div>

      <div>
        <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
          </span></div>

      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt;">Pursuant to the Amendment, the Company agreed to guaranty all payments and other obligations of Eterna LLC owed to Factor Limited under the Amended Factor License Agreement.
          The exclusive license granted to Eterna LLC under the Amendment is subject to sublicenses or other rights previously granted by Factor Limited to third parties as of November 1, 2022. The term of the license granted under the Amendment is five
          years from the Amendment Effective Date and is extendable for an additional two and a half years if Eterna LLC receives at least $100 million from sublicenses granted by it with respect to the sublicensing opportunities contemplated by the
          Amendment. Eterna LLC may not develop or commercialize products by itself under the license granted in the Amendment, but it maintains its right to develop and commercialize the products specified under the License Agreement.</div>

      </div>

      <div>
        <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
          </span></div>

      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt;">Under the Amendment, Eterna LLC agreed to pay to Factor Limited 20% of the sublicense fees received by Eterna LLC under the sublicenses granted with respect to the
          sublicensing opportunities that are identified during the first five-year term of the license granted under the Amendment and 30% of any sublicense fees received by Eterna LLC under the sublicenses granted with respect to the sublicensing
          opportunities that are identified during the potential two and a half year extension period of the term of the license granted under the Amendment. Eterna LLC also agreed to pay the expenses incurred by Factor Limited in preparing, filing,
          prosecuting and maintaining the Factor Patents and has agreed to bear all costs and expenses associated with enforcing and defending the Factor Patents in any action or proceeding arising from pursuit of sublicensing opportunities under the
          license granted in the Amendment.</div>

      </div>

      <div>
        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';">Additionally, during the term of the license granted under the
            Amendment, Eterna LLC may identify two opportunities as &#8220;Surviving Opportunities&#8221; for which Eterna LLC may pursue sublicense for up to four years following termination of the license granted under the Amendment and collect any compensation
            received under any such sublicenses, subject to payment to Factor Limited of the fees to which it is entitled under the Amendment. Upon the termination of the license granted under the Amendment and in the event the parties are unable to
            resolve any dispute regarding the Surviving Opportunities, or at Eterna LLC&#8217;s election, Factor Limited agreed to assume the Surviving Opportunities and pay to Eterna LLC 80% of all amounts received by Factor Limited pursuant to sublicenses
            entered into with respect to such Surviving Opportunities within the four-year period following such termination.</span></div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>

      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div>
          <div>
            <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">On September 9, 2022, the Company, entered into a Master Services Agreement with Factor, pursuant to which Factor has agreed
              to provide services to the Company as agreed between the Company and Factor and set forth in one or more work orders under such agreement (including the first work order thereunder, the &#8220;<span style="font-size: 10pt; font-family: 'Times New Roman';"><span style="text-decoration: underline;">MSA</span></span>&#8221;). Under the MSA, Factor agreed to provide the Company with mRNA cell engineering research support services, including access to certain facilities, equipment, materials and training, and the Company agreed to pay
              Factor an initial fee of $5,000,000, payable in twelve equal monthly installments of $416,667. Following the initial 12-month period, the Company agreed to pay Factor a monthly fee of $416,667 until such time as the first work order under the
              MSA is terminated.</div>

            <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
            </div>

          </div>

        </div>

      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      </div>

      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">
        <div>
          <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The Company may terminate the first work under the MSA on or after the second anniversary of the date of the MSA, subject to
            providing Factor with 120 days&#8217; prior notice. Factor may terminate such work order only on and after the fourth anniversary of the date of the MSA, subject to providing the Company with 120 days&#8217; prior notice. The MSA contains customary
            confidentiality provisions and representations and warranties of the parties, and the MSA may be terminated by ether party upon 30 days&#8217; prior notice, subject to any superseding termination provisions contained in a particular work order.</div>

          <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';">On October 8, 2022, the Company entered into an option agreement
            (the &#8220;<span style="text-decoration: underline;">Option Agreement</span>&#8221;) with Exacis, pursuant to which Exacis granted the Company the option to negotiate and enter into an exclusive worldwide license to certain of the technology licensed by Exacis for the treatment of cancer in
            humans. The Option Agreement provided that the Company would pay Exacis a fee of $250,000 for the option, which would be creditable against the fees or purchase price payable under any such license if entered into by the Company in accordance
            with Option Agreement. The Company did not exercise the option, and the Option Agreement terminated on December 31, 2022.</span></div>

      </div>

      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
      </div>

      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">
        <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The foregoing description of the Novellus Acquisition Agreement, the License Agreement, the Amendment and the MSA is only a summary and is
          qualified in its entirety by reference to the full text of the Novellus Acquisition Agreement, the License Agreement, the Amendment and the MSA, which the Company filed as Exhibit 10.1 to its Current Report on Form 8-K filed with the SEC on July
          19, 2021 (filed at 4:05 p.m. EDT), as Exhibit 10.3 to its Current Report on Form 8-K filed with the SEC on April 30, 2021, as Exhibit 10.1 to its Current Report on Form 8-K filed with the SEC on November 22, 2022, and as Exhibit 10.1 to its
          Current Report on Form 8-K filed with the SEC on September 15, 2022, respectively, and are incorporated by reference in this Item 5.02.</div>

      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div>
        <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Forward-Looking Statements</div>

        <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
          </span></div>

      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Certain matters discussed in this Current Report on Form 8-K constitute forward-looking statements within the meaning of the Private
        Securities Litigation Reform Act of 1995, including statements relating to the Transfer. These forward-looking statements involve many risks and uncertainties that could cause actual results to differ materially from those expressed or implied by
        such statements, including, without limitation, that the common stock will continue to trade under the symbol &#8220;ERNA&#8221;. These forward-looking statements speak only as of the date hereof, and the Company expressly disclaims any obligation or
        undertaking to disseminate any updates or revisions to any forward-looking statement contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is
        based. Please refer to the publicly filed documents of the Company, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, for risks and uncertainties related to the Company&#8217;s business which may affect the
        statements made in this this Current Report on Form 8-K.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div><br />
        </div>

      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 45pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 9.01</td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="font-weight: bold;">Financial Statements and Exhibits.</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">(d) Exhibits.</div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;"> <br />
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exhibit</div>
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Number</div>
              </div>
            </td>

    <td style="width: 1%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;"><br />
            </td>

    <td style="width: 89%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
              <div>
                <div style="text-align: center; font-weight: bold;">Description</div>
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: center;"><a href="brhc10046238_ex10-1.htm">10.1#</a></div>
            </td>

    <td style="width: 1%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);"><br />
            </td>

    <td style="width: 89%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; color: rgb(0, 0, 0);">Angel Offer Letter, dated December 30, 2022, by and among Eterna Therapeutics Inc. and Dr. Matthew Angel.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" rowspan="1">&#160;</td>

    <td style="width: 1%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" rowspan="1">&#160;</td>

    <td style="width: 89%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: center;">104</div>
            </td>

    <td style="width: 1%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);"><br />
            </td>

    <td style="width: 89%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" rowspan="1">&#160;</td>

    <td style="width: 1%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" rowspan="1">&#160;</td>

    <td style="width: 89%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" rowspan="1">&#160;</td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">#</td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">Management contract or compensation plan or arrangement.</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">SIGNATURE</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto
        duly authorized.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49.75%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><br />
            </td>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="2">
              <div style="text-align: left; font-variant: small-caps;">Eterna Therapeutics Inc.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 49.75%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><br />
            </td>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="2"><br />
            </td>

  </tr>

  <tr>

    <td style="width: 49.75%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: left;">Dated: <span style="color: rgb(0, 0, 0);">January 4, 2023</span></div>
            </td>

    <td style="width: 2.97%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: left;">By:</div>
            </td>

    <td style="width: 47.03%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: left;">/s/ <span style="font-variant: small-caps;">Andrew Jackson</span></div>
            </td>

  </tr>

  <tr>

    <td style="width: 49.75%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><br />
            </td>

    <td style="width: 2.97%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><br />
            </td>

    <td style="width: 47.03%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: left;">Andrew Jackson</div>
            </td>

  </tr>

  <tr>

    <td style="width: 49.75%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><br />
            </td>

    <td style="width: 2.97%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><br />
            </td>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: left;">Chief Financial Officer</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

    </div>

  </div>

  <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>brhc10046238_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc
         Document created using Broadridge PROfile 22.12.1.5105
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <font style="font-size: 10pt;"> </font>
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exhibit 10.1</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zee51c5b392f448b9bf88c74a0a28ac5c">

          <tr>
            <td style="width: 100%; vertical-align: top; font-size: 10pt; text-align: center;"><img src="image01.jpg"></td>
          </tr>

      </table>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Eterna Therapeutics Inc.</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">10355 Science Center Drive, Suite 150</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">San Diego, CA 92121</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">December 30, 2022</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Matthew Angel</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">via email:&#160; matt.angel@eternatx.com</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Dear Matthew:</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">On behalf of Eterna Therapeutics, Inc. (formerly known as Brooklyn ImmunoTherapeutics, Inc.), a Delaware corporation (the &#8220;Company&#8221;), I am pleased to extend an offer
        of employment to you to serve as the Company&#8217;s President and Chief Executive Officer, with an employment start date anticipated to be on or about January 1, 2023 (the &#8220;Start Date&#8221;).&#160; In such capacity, you will report directly to the Board of
        Directors of the Company (the &#8220;Board&#8221;).&#160; You will be responsible for such duties as are normally associated with such position and as otherwise assigned from time to time.&#160; While you are serving as Chief Executive Officer, you will serve, or be
        nominated to serve, as applicable, as a member of the Board.&#160; Your principal place of employment will be in Cambridge, Massachusetts, with travel required from time-to-time as necessary for the performance of your job duties.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">This offer and your employment relationship will be subject to the terms and conditions of this letter agreement.&#160; Upon execution of this letter agreement, you and the
        Company each agree to negotiate in good faith and execute and deliver a formal, written employment agreement within 30 days following the date hereof, consistent with the terms of this letter and containing such other terms and conditions as are
        mutually acceptable to you and the Company (the &#8220;Employment Agreement&#8221;), including restrictive covenant provisions that appropriately take into account your affiliations with Factor Bioscience Inc. (&#8220;Factor&#8221;) and its affiliated entities. The
        Parties further contemplate that the Employment Agreement will include severance provisions and an assignment of certain inventions by you consistent with the Company&#8217;s agreements with Factor and its affiliated entities.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><u>Compensation</u></div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Base Salary</font><font style="font-size: 10pt;">: From and after your Start Date,
          you will be paid an annualized base salary of $350,000.00. This position is an exempt position, which means you are paid for the job and not by the hour.&#160; Accordingly, you will not receive overtime pay if you work more than 8 hours in a workday
          or 40 hours in a workweek.&#160; Your base salary will be payable in accordance with the Company&#8217;s standard payroll policies and subject to adjustment pursuant to the Company&#8217;s policies as in effect from time to time.</font></div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Signing Bonus</font><font style="font-size: 10pt;">: Within ten calendar days
          following your Start Date, you will receive a cash signing bonus equal to $210,959.&#160; You and the Company acknowledge that you have been serving as Interim President and Chief Executive Officer without pay since May 26, 2022.&#160; This signing bonus
          represents salary you would have earned for the period during which you served as Interim Chief Executive Officer, had this letter agreement been in effect.</font></div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Performance Bonus</font><font style="font-size: 10pt;">: During and, in certain
          circumstances, after your employment with the Company, you will eligible to receive a performance bonus equal to 2% of the gross proceeds actually received by the Company pursuant to all licensing, option, collaboration, partnership, joint
          venture, settlement, other similar agreements entered into by the Company, or other actions, judgments, or orders that generate cash proceeds to the Company, that are originated, negotiated and/or entered into by the Company during your
          employment (commencing on May 26, 2022) with the Company (the &#8220;Performance Bonus&#8221;).&#160; Such Performance Bonuses will be paid on or before the last day of the month following each quarter in which the proceeds are received in accordance with the
          Company&#8217;s payroll practices then in effect (and subject to all required tax deduction and other legally required withholding), and, unless your employment is terminated by the Company for Cause (which shall have the meaning as mutually agreed in
          the Employment Agreement) or you voluntarily resign from the Company (other than for Good Reason, which shall have the meaning as mutually agreed in the Employment Agreement), the Performance Bonus will remain a continuing obligation of the
          Company that will survive any other termination of your employment with the Company. For clarity, the Company&#8217;s obligation to pay, and your right to receive, the Performance Bonus will immediately terminate if you voluntarily resign other than
          for Good Reason or are terminated for Cause. Notwithstanding the foregoing, the obligation to continue paying the Performance Bonus following your termination is contingent upon you having remained employed by the Company (unless terminated by
          the Company without Cause or terminated by you for Good Reason) for two years following the effective date of the applicable agreement/arrangement underlying the applicable Performance Bonus.&#160; For example, if a license agreement is entered into
          on February 1, 2023, then you shall be entitled to continue to receive a Performance Bonus following your termination with respect to such agreement only if you remain employed by the Company until February 1, 2025 or if your employment is
          terminated by the Company without Cause or terminated by you for Good Reason.</font></div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Equity Compensation</font><font style="font-size: 10pt;">: During the term of your
          employment with the Company, you will be awarded a new time-based stock option grant (the &#8220;Option Grant&#8221;) to acquire shares of the Company&#8217;s common stock (&#8220;Shares&#8221;) under the Company&#8217;s Restated 2020 Stock Incentive Plan, as amended and restated
          from time to time (the &#8220;Current Plan&#8221;).&#160; The number of Shares underlying the Option Grant will be calculated on the Start Date so that your aggregate total outstanding option awards (i.e. including previously issued equity awards) will equal 5%
          of the issued and outstanding Shares of the Company as of the Start Date.&#160; The per share exercise price of the Option Grant will equal the Fair Market Value (as defined in the Current Plan) of such Shares on the date of grant.</font></div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Option Grant will be awarded within ten business days following the Start Date.&#160; The Option Grant will vest such that fifty percent (50%) of the aggregate of the
        Option Grant and the option that was granted to you on August 1, 2022 will be fully vested on the Start Date and the remaining portion of the Option Grant, if any, will vest in substantially equal monthly installments over the 36 months following
        the Start Date.&#160; The Option Grant will become fully vested on a liquidity event (as defined in your award agreement or pursuant to the terms of the Current Plan), including without limitation a merger, sale or other transaction in which the
        Company&#8217;s shareholders before the transaction hold less than 50% of the resulting Company equity after the transaction, or a sale of all or substantially all of the Company&#8217;s assets.</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Option Grant will have a ten-year term and will provide for the right to exercise by means of a &#8220;cashless exercise sale and remittance procedure&#8221; (as described in
        the Current Plan).</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">If your employment is terminated by the Company without Cause, by you for Good Reason, or due to your death or Disability (which shall have the meaning as mutually
        agreed in the Employment Agreement), the Option Grant will vest in the amount that would have vested had you remained employed for 12 months after such termination. In addition, notwithstanding anything to the contrary in any option agreement, if
        your employment is terminated by the Company without Cause, by you for Good Reason, or due to your death or Disability, any other options that you receive (including the option that was granted to you on August 1, 2022) will vest in the amount that
        would have vested had you remained employed for 12 months after such termination. Notwithstanding anything to the contrary in any option agreement, all options that you receive (including the option that was granted to you on August 1, 2022) will
        remain exercisable for 12 months after termination by the Company without Cause, by you for Good Reason, or due to your death or Disability (but not beyond the end of the applicable option term). Your continued employment with the Company through
        the applicable vesting date will be a condition precedent to the vesting of the Option Grant, except as provided in the preceding sentences.&#160; The Option Grant will be granted under, and governed by, the Current Plan and a grant instrument with
        mutually agreed upon terms that are consistent with the foregoing terms.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Commencing in 2023, you will be eligible to receive annual equity awards under an applicable equity incentive plan of the Company as then in effect, as determined by
        the Compensation Committee of the Board in its discretion.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><u>Benefits</u></div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Standard benefits</font><font style="font-size: 10pt;">: You will be eligible to
          participate in all employee benefit plans that the Company customarily makes available to its executive employees. You will be provided with flexible vacation and paid sick leave, consistent with the Company&#8217;s policies in effect from time to time
          and/or applicable law. The Company reserves the right to change or eliminate the employee benefit plans on a prospective basis, at any time, effective upon notice to you.</font></div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Reimbursable expenses</font><font style="font-size: 10pt;">: The Company will
          reimburse you for all reasonable lodging, transportation, travel, entertainment, and other business expenses that you incur while performing your duties hereunder, in accordance with the Company&#8217;s expense reimbursement policies and procedures.&#160;
          To obtain reimbursement, expenses must be submitted promptly with appropriate supporting documentation and will be reimbursed in accordance with the Company&#8217;s policies.&#160; Any reimbursement you are entitled to receive will (a) be paid no later than
          the last day of your tax year following the tax year in which the expense was incurred, (b) not be affected by any other expenses that are eligible for reimbursement in any tax year and (c) not be subject to liquidation or exchange for another
          benefit.</font></div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><u>At-Will Employment</u></div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">If you accept our offer, your employment with Company will be &#8220;at will.&#8221;&#160; This means your employment is not for any specific period and can be terminated by you at any
        time for any reason.&#160; Likewise, the Company may terminate the employment relationship at any time, with or without cause or advance notice.&#160; Any change to the at-will employment relationship must be by a specific, written agreement signed by you
        and the Chair of the Board.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><u>Third Party Rights</u></div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">By accepting this offer, you represent that, other than with respect to Factor and its affiliated entities, you are not a party to any other agreement, covenant, or
        restriction which will or could interfere with your ability to fully and satisfactorily provide the services for which you are being offered employment and employed by the Company.&#160; During your employment with the Company, you will not breach any
        agreement between you and any third party to keep in confidence proprietary information, knowledge or data belonging to that third party that was acquired by you prior to your employment with the Company.&#160; In addition, you agree that you will not
        disclose to the Company, or induce the Company to use, any confidential or proprietary information or material belonging to any previous or other current employer or others, unless such disclosure is required or authorized under the Company&#8217;s
        agreements with such employer or others or is otherwise authorized by such employer or others.&#160; You agree not to enter into any agreement, whether written or oral, in conflict with your promises in this provision.&#160; You also agree to keep
        confidential all confidential information owned or possessed by the company in accordance with any third-party agreements pertaining to confidentiality.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><u>No Conflict of Interest</u></div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">During your employment with the Company, you agree that you will not engage in any work, paid or unpaid, that creates an actual conflict of interest with the Company,
        other than with respect to Factor and its affiliated entities.&#160; Such work will include, but is not limited to, competing with the Company in any way, or acting as an officer, director, employee, consultant, stockholder, volunteer, lender, or agent
        of any business enterprise of the same nature as the Company (other than Factor and its affiliated entities), or any business enterprise which is in direct competition with the Company.&#160; If the Company believes such a conflict exists, the Company
        may ask you to choose to discontinue the other work or resign employment with the Company.&#160; For the avoidance of doubt, the Company will not ask you to reduce or discontinue your affiliations with Factor and its affiliated entities.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><u>Outside Activities</u></div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Notwithstanding anything in this letter agreement or any Company policy to the contrary, the Company acknowledges that you currently serve, and during your employment
        with the Company will continue to serve, as an employee, officer, and director of Factor and its affiliated entities and as a member of the Scientific Advisory Board of Exacis Biotherapeutics Inc.&#160; The Company approves of your affiliations with
        Factor and its affiliated entities, and agrees that you shall not be deemed to be in violation of any obligation to the Company by virtue or as a result of your affiliations with Factor and its affiliated entities.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><u>Indemnification</u></div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">You and the Company agree to comply with the terms of the Indemnification Agreement dated May 26, 2022, which is incorporated into this letter agreement by this
        reference.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><u>Legal Fees</u></div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Within 30 days of the Start Date, but in no event later than March 15, 2023, the Company will reimburse your legal fees and expenses in connection with the review,
        preparation, negotiation and execution of this letter agreement, your Option Grant and related documents; provided such reimbursement will not exceed $30,000.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><u>Tax Withholding; Internal Revenue Code</u></div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">All payments and taxable benefits under this letter agreement will be made subject to applicable taxes and withholding.&#160; All payments and option grants under this
        letter agreement shall be made consistently with Section 409A of the Internal Revenue Code.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><u>Severability</u></div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The invalidity or unenforceability of any provision of this letter agreement will not affect the validity or enforceability of the other provisions of this letter
        agreement, which will remain in full force and effect.&#160; Moreover, if any provision is found to be excessively broad in duration, scope or covered activity, the provision will be construed, and to the extent necessary will be deemed to be amended,
        to be enforceable to the maximum extent compatible with applicable law.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><u>Contingencies</u></div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">You agree to execute the following documents on the date hereof:</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd4cb7228430a4a929b7aab5bff668ab4">

          <tr>
            <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">This letter agreement, and</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z828b1e3fac394936a383f6166e8194dd">

          <tr>
            <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">The Company&#8217;s Code of Conduct and Ethics policy attached hereto as Exhibit A.</div>
            </td>
          </tr>

      </table>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Company acknowledges and agrees that you shall not be deemed to be in violation of any provision of the Company&#8217;s Code of Conduct and Ethics policy by
        virtue or as a result of your affiliations with Factor and its affiliated entities.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">You also agree to:</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zed635df1ce854a5a9da8bea127749b48">

          <tr>
            <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">Comply with Company&#8217;s policies and procedures, consistent with the above, and</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zba0c2b90c3eb4a1daedadcee7dedc5ee">

          <tr>
            <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">Comply with federal I-9 requirements</div>
            </td>
          </tr>

      </table>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Both Parties agree to negotiate in good faith and execute and deliver the Employment Agreement within 30 days following the date
        hereof.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><u>Complete Agreement</u></div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">This letter agreement (including Exhibit A attached hereto) constitutes the entire agreement between you and the Company relating to this subject matter and
        supersedes all prior or contemporaneous agreements, understandings, negotiations, or representations, whether oral or written, express or implied, on this subject.&#160; This letter agreement may not be modified or amended except by a specific, written
        agreement signed by you and the Company&#8217;s authorized signatory.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">To indicate your acceptance, please sign and return the enclosed copy of this letter agreement to me by December 31, 2022.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">If you have any questions, regarding this letter agreement or employment with the Company, please feel free to contact Donna Parkinson, HR Specialist via email at
        donna.parkinson@eternatx.com. The Company looks forward to your favorable reply and to a productive and enjoyable work relationship.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Sincerely,</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zc7874d1bac13457ebfff3ec3e7c1e3b8">

          <tr>
            <td colspan="3" style="vertical-align: top; font-size: 10pt;">
              <div style="text-align: justify; font-family: 'Times New Roman';">Eterna Therapeutics, Inc.</div>
            </td>
          </tr>
          <tr>
            <td colspan="3" style="vertical-align: top; font-size: 10pt;"><br>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">
              <div style="text-align: justify; font-family: 'Times New Roman';">By:</div>
            </td>
            <td style="width: 45%; vertical-align: top; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-style: italic;">/s/ Donna Parkinson</div>
            </td>
            <td style="width: 50%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;"><br>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: justify; font-family: 'Times New Roman';">Name:</div>
            </td>
            <td style="width: 45%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: justify; font-family: 'Times New Roman';">Donna Parkinson</div>
            </td>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;"><br>
            </td>
          </tr>
          <tr>
            <td colspan="2" rowspan="1" style="width: 5%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: justify; font-family: 'Times New Roman';">Title: HR Specialist</div>
            </td>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;"><br>
            </td>
          </tr>
          <tr>
            <td colspan="3" style="vertical-align: top; font-size: 10pt;"><br>
            </td>
          </tr>
          <tr>
            <td colspan="3" style="vertical-align: top; font-size: 10pt;">
              <div style="text-align: justify; font-family: 'Times New Roman';">ACCEPTED:</div>
            </td>
          </tr>
          <tr>
            <td colspan="3" style="vertical-align: top; font-size: 10pt;">
              <div style="text-align: justify; font-family: 'Times New Roman';">Employee Name: Matthew Angel</div>
            </td>
          </tr>
          <tr>
            <td colspan="3" style="vertical-align: top; font-size: 10pt;"><br>
            </td>
          </tr>
          <tr>
            <td rowspan="1" colspan="2" style="vertical-align: top; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-style: italic;">/s/ Matthew Angel</div>
            </td>
            <td rowspan="1" style="width: 50%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;"><br>
            </td>
          </tr>
          <tr>
            <td colspan="3" style="vertical-align: top; font-size: 10pt;">
              <div style="text-align: justify; font-family: 'Times New Roman';">(Signature)</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="za65fad84b7eb4dca9ead2e0d90b195a8">

          <tr>
            <td colspan="4" style="vertical-align: top; font-size: 10pt;"><br>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">
              <div style="text-align: justify; font-family: 'Times New Roman';">Dated:</div>
            </td>
            <td style="width: 15%; vertical-align: top; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; font-family: 'Times New Roman'; text-indent: 0pt; margin-left: 9pt;">12/30/2022</div>
            </td>
            <td style="width: 40%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;"><br>
            </td>
            <td style="width: 40%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;"><br>
            </td>
          </tr>

      </table>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">EXHIBIT A</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Code of Conduct and Ethics</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(See Attached)</div>
      <div style="text-align: left; font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; font-size: 10pt;">
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
  <font style="font-size: 10pt;"> </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>erna-20221229.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 22.12.1.5105 Broadridge-->
<xs:schema targetNamespace="http://eternatx.com/20221229" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:erna="http://eternatx.com/20221229" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="erna-20221229_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="erna-20221229_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://eternatx.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>erna-20221229_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 22.12.1.5105 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract_lbl" xml:lang="en-US" id="dei_CoverAbstract_lbl">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:title="label: CoverAbstract to dei_CoverAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications_lbl" xml:lang="en-US" id="dei_WrittenCommunications_lbl">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:title="label: WrittenCommunications to dei_WrittenCommunications_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial_lbl" xml:lang="en-US" id="dei_SolicitingMaterial_lbl">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementTenderOffer_lbl">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer_lbl">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber_lbl" xml:lang="en-US" id="dei_EntityFileNumber_lbl">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:title="label: EntityFileNumber to dei_EntityFileNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber_lbl">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode_lbl">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany_lbl">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine1_lbl">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine2_lbl">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine3_lbl">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" id="dei_EntityAddressCityOrTown_lbl">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" id="dei_EntityAddressStateOrProvince_lbl">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry_lbl" xml:lang="en-US" id="dei_EntityAddressCountry_lbl">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" id="dei_EntityAddressPostalZipCode_lbl">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode_lbl" xml:lang="en-US" id="dei_CityAreaCode_lbl">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:title="label: CityAreaCode to dei_CityAreaCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber_lbl" xml:lang="en-US" id="dei_LocalPhoneNumber_lbl">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle_lbl" xml:lang="en-US" id="dei_Security12bTitle_lbl">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:title="label: Security12bTitle to dei_Security12bTitle_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US" id="dei_NoTradingSymbolFlag_lbl">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol_lbl" xml:lang="en-US" id="dei_TradingSymbol_lbl">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:title="label: TradingSymbol to dei_TradingSymbol_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName_lbl" xml:lang="en-US" id="dei_SecurityExchangeName_lbl">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName_lbl" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>erna-20221229_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 22.12.1.5105 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://eternatx.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="erna-20221229.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image01.jpg
<TEXT>
begin 644 image01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  [ &L# 2(  A$! Q$!_\0
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I$L4"#A5_G[FK-%14K2FN79=D72H1IOFW?=[_ ->@4445D;A1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139933888049824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Dec. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 29,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-11460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Eterna Therapeutics Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000748592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">31-1103425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1035 Cambridge Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 18A<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">582-1199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.005 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ERNA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>brhc10046238_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="erna-20221229.xsd" xlink:type="simple"/>
    <context id="c20221229to20221229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
        </entity>
        <period>
            <startDate>2022-12-29</startDate>
            <endDate>2022-12-29</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20221229to20221229"
      id="Fact_2f354ac69bcc48c993312065f84aa0fc">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20221229to20221229"
      id="Fact_89b099ef14e5497f9d6decf465b93fa2">0000748592</dei:EntityCentralIndexKey>
    <dei:SecurityExchangeName
      contextRef="c20221229to20221229"
      id="Fact_b552152fa97b4f6c96e787e7c685aac8">NASDAQ</dei:SecurityExchangeName>
    <dei:DocumentType
      contextRef="c20221229to20221229"
      id="Fact_93296fbc28f74ea6a7680ba310595bde">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20221229to20221229"
      id="Fact_c8e73d47c549437dad8f09f985707a36">2022-12-29</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20221229to20221229"
      id="Fact_aba8908c97c8492190ed2c9006033c56">Eterna Therapeutics Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20221229to20221229"
      id="Fact_fe49c90992fa4568bdab8fa5de9393bd">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20221229to20221229"
      id="Fact_1d4eb8b2a66e4171a2900f93ca312e8a">001-11460</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20221229to20221229"
      id="Fact_99ea217ba72c4119b2ada9cb6fed5bbd">31-1103425</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20221229to20221229"
      id="Fact_32ca7ee9fe764a599b9d70ef8761804b">1035 Cambridge Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="c20221229to20221229"
      id="Fact_9223e44ac85a405787cfba4396c13499">Suite 18A</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="c20221229to20221229"
      id="Fact_490bed6ccbba416cb00fbf1f39bbc072">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20221229to20221229"
      id="Fact_490274e502304678bcac01205363dee7">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20221229to20221229"
      id="Fact_7450cc16f2c3403c80be86da31c38d15">02141</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20221229to20221229"
      id="Fact_7d7eb64598e2456999c7d1ccc182f4a6">212</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20221229to20221229"
      id="Fact_29b751987e114c24bd15a6b0ea602deb">582-1199</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20221229to20221229"
      id="Fact_ba47809d5fd5475ca1d58836870c8e7f">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20221229to20221229"
      id="Fact_734f50472dd844119f6ca9bee37e5c86">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20221229to20221229"
      id="Fact_12753308bcdb4f37a4524acbcadd3f65">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20221229to20221229"
      id="Fact_e62d4b89adb54106bc803cad4748e815">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20221229to20221229"
      id="Fact_59a3fbc5a7f744eb94d03f8386643469">Common Stock, par value $0.005 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20221229to20221229"
      id="Fact_9fe88d82eaa144c5b6bf3ef976394d04">ERNA</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20221229to20221229"
      id="Fact_ff3226c8b6414e38832cc61134961aa6">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M(U^SQM2U2 )=ETQXNM R6@E8$0U="8.M>P!%+1R'G6]4(RPN.2LDU OMC3'
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M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ ;T0D5APX9>H_ 0  / (   \
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M<F]P<R]A<' N>&UL4$L! A0#%     @ ;T0D5HQ/XP_O    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ ;T0D
M5IE<G",0!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " !O1"16JZ",LV$$   ^$0  &
M@($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ ;T0D
M5I^@&_"Q @  X@P   T              ( !I0P  'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    " !O1"16EXJ[',     3 @  "P              @ &!#P
M7W)E;',O+G)E;'-02P$"% ,4    " !O1"16'#AEZC\!   \ @  #P
M        @ %J$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ ;T0D5B0>
MFZ*M    ^ $  !H              ( !UA$  'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ ;T0D5F60>9(9 0  SP,  !,
M     ( !NQ(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @
&!10

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="brhc10046238_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName -  brhc10046238_8k.htm 11</Log>
  </Logs>
  <InputFiles>
    <File doctype="8-K" original="brhc10046238_8k.htm">brhc10046238_8k.htm</File>
    <File>brhc10046238_ex10-1.htm</File>
    <File>erna-20221229.xsd</File>
    <File>erna-20221229_lab.xml</File>
    <File>erna-20221229_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "brhc10046238_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "brhc10046238_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "erna-20221229_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "erna-20221229_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "erna-20221229.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 29,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "erna",
   "nsuri": "http://eternatx.com/20221229",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10046238_8k.htm",
      "contextRef": "c20221229to20221229",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000100 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://eternatx.com/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10046238_8k.htm",
      "contextRef": "c20221229to20221229",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001140361-23-000340-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-23-000340-xbrl.zip
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MDL<7XC/\8@#E#H>V-;0#/AV[3C#RIB,QGHS%V!M-AIQ[DRV ^GQX]O[P[PV
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MJ!@/8::Z*/+'PATYP^E$V,YP-)U.O;%O>2"=)G;@\&VBXO!/71"]6J\4/R9
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M6Y=%=]Q=-<E7.7FC#YPN[5VFF&2BLY\^G:Q<-0P?TER(*=/.2!;(*LM8GE,
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M?X:=9F0H_2/\HTZ1G@ILT %"EP2Q-9T.*_?7E&^2?1#155$UZ/J2:30YLHU
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MR>Z;/3?Q5P?X89;/(_CP_P%02P,$%     @ ;T0D5D9QI1OY&P  \HL  !<
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MH,BE;T-&$3P/A$UPS>]3G4UH('^)JMR%"1,%(*$33@JDV7[;QO9<2 %^A+&
M8<H']$(\A]Y2]@1FO@$L+XY(S7C?$6&W4S.##UCNP810K"AV5JC>BIQ66'(Y
M/W..$=S*6ZIL^WR<A4K4F#TF)<"B8LIJX9ED!EP]C30SQ;? 2Q;Y%%B:=0WI
MH(:1K H\U.T>Q>A8\6J\@V21F" 5."!20&)[V6/*H^1():\AFL[JM$DG,6/D
M:N*8V[V(H$Q-C@XFIAU10NLB5V6Y(GV@$S$&=CFA)1JC!GXM ;%BFU$!+@;
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M%Z%)#0=(<"8WN+'JH\&>0ZPD^KX+_KF"(@7+S;\@0]MP]9ZJMH7C.NIAQ)]
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M!\6\Y&GF8BO$/(XJLJN_4$L#!!0    ( &]$)%9.U2<Q?P@  '58   5
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M3 +"3I9/V5B:T0,E*],^D)KE*U<C]SM&D@QE!!ER)YT3]X$$ZQ5.LGOFJ.
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ME5@U:EN#:W!V2[&]$SO2MES!-],@630@VNOVF;QR.Z Z,*3)16'U[JM"+I*
MT"="\P'<9>S:_8RLV3GDY8R$\*5THPRI6FHR6M>,U=]MY33IREX_]0ZBBB3E
M&Y1K$:&HU".>,(2":@8$^:8=@XK+FBR76(-^^BJT\Q6FRRA9_D;)<_9X1E9/
M?@)?[%N54F$9E*T+"O1U6TBV+NP%9,X4A2,4J)"@4C.$6K'O+7G5)D"U 2;)
M-6'Q[:L63L.0,9B6_UQ&"9Z"E6#1274 ZEI7 >#JM@;,'=@KP)0G^"\#;\0'
MQ"7H.AG$V<*VI^05RP_1#Z3([!L]]T>^UY!\KR'Y7B?D>UV3[WTC^5X#\N^?
MR3#)]YJ2[[V>?*^.?&_?Y,\:DC]K2/ZL$_)G79,_^T;R9TW(9QLVT*/^K"G[
ML]>S/ZMC?[87]L_8QVMZ3YX3&_FZ"N*^JG)%_<ZS$^8U^T;$*UD:[SS.OQ5S
MQ8!(!W81XAQ><@OENP20<=6O9\+SK]C7](:2KU&B ==$"K&N25T!KQAW0CW<
M1R/TH52-_^UM(2$;4!&8]ABJ!,M>6,I!R0)K G3N^]!?W':R'O=E"7C0%Q)G
M1_S"L)O#O>3=[%A?2=$/]$5P0'BK.P8>X/45MAW=RUN[X*&]ZM0SOC<DS?SX
M[^C)^%L!FQ!"61&Z EJR[01KJ(=&<.N)&N*%!#'-8&[N6_<5 MZX Q;LI1P0
M?L"U^Q+@%U.G%/L ]%"HG* <:O/6AXJ1LY<^Z)[&=SZHTGE^J<V;!D GN '$
MOG R@575]FT/6F;WE/$77<4WCR2!_^^,*5Q.1@^W($XU<T6=P==$'BB?YZTH
M;Q[$_R8P;@RI7TR91%4I:(0=>GBB'@=KRBIAZBWN^4 54DSA<E)ZN,VS](J9
MLR?I85_C<_20?)Y_1.0!3;V?%C\C(=KSD_2FW2'U*RICJ2JWS]"##MUC>47N
MJ<]?7'CWLEJ0&'@$TJ(HIP8J6O )^+E"U&QMHM24,;\BJ(R@(C2 !R5M>T4:
M+:Y,*R 6P!I]NF=6ZECA!XR5DU)B+0B5G%RQ"9F:J-2U<QG&_7(([P*I63R9
M/4DFJ -R^SMUGV^"1[89&'@@QB913N&RQ,%IO&KH^E0.>->=SK64N8@@$1K
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MWT;DB_R9]L?_ 5!+ 0(4 Q0    ( &]$)%9YYNU..BT  .<" 0 3
M      "  0    !B<FAC,3 P-#8R,SA?.&LN:'1M4$L! A0#%     @ ;T0D
M5D9QI1OY&P  \HL  !<              ( !:RT  &)R:&,Q,# T-C(S.%]E
M>#$P+3$N:'1M4$L! A0#%     @ ;T0D5H74W6I% P  .@\  !$
M     ( !F4D  &5R;F$M,C R,C$R,CDN>'-D4$L! A0#%     @ ;T0D5D[5
M)S%_"   =5@  !4              ( !#4T  &5R;F$M,C R,C$R,CE?;&%B
M+GAM;%!+ 0(4 Q0    ( &]$)%; VS/$V@4  /(^   5              "
M ;]5  !E<FYA+3(P,C(Q,C(Y7W!R92YX;6Q02P4&      4 !0!+ 0  S%L
#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
